(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Stephane Oudard presented data on patient-reported health-related quality of life (HRQoL) in the context of the ACIS trial (NCT02257736). This phase III trial randomized patients with metastatic castration resistant prostate cancer (mCRPC) to receive either abiraterone acetate and prednisone with or without apalutamide. In previously presented analyses, the combination regime demonstrated improved radiographic progression-free survival (rPFS) with 7.4-month improvement in median rPFS (primary endpoint) (p < 0.0001).